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Genome-wide association study of over 40,000 bipolar disorder 
cases provides new insights into the underlying biology
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Abstract
Bipolar disorder (BD) is a heritable mental illness with complex etiology. We performed a 
genome-wide association study (GWAS) of 41,917 BD cases and 371,549 controls of European 
ancestry, which identified 64 associated genomic loci. BD risk alleles were enriched in genes in 
synaptic signaling pathways and brain-expressed genes, particularly those with high specificity of 
expression in neurons of the prefrontal cortex and hippocampus. Significant signal enrichment was 
found in genes encoding targets of antipsychotics, calcium channel blockers, antiepileptics, and 
anesthetics. Integrating eQTL data implicated 15 genes robustly linked to BD via gene expression, 
encoding druggable targets such as HTR6, MCHR1, DCLK3 and FURIN. Analyses of BD 
subtypes indicated high but imperfect genetic correlation between BD type I and II and identified 
additional associated loci. Together, these results advance our understanding of the biological 
etiology of BD, identify novel therapeutic leads, and prioritize genes for functional follow-up 
studies.
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Bipolar disorder (BD) is a complex mental disorder characterized by recurrent episodes of 
(hypo)mania and depression. It is a common condition affecting an estimated 40 to 50 
million people worldwide1. This, combined with the typical onset in young adulthood, an 
often chronic course, and increased risk of suicide2, make BD a major public health concern 
and a major cause of global disability1. Clinically, BD is classified into two main subtypes: 
bipolar I disorder, in which manic episodes typically alternate with depressive episodes, and 
bipolar II disorder, characterized by the occurrence of at least one hypomanic and one 
depressive episode3. These subtypes have a lifetime prevalence of ~1% each in the 
population4,5.
Family and molecular genetic studies provide convincing evidence that BD is a 
multifactorial disorder, with genetic and environmental factors contributing to its 
development6. On the basis of twin and family studies, the heritability of BD is estimated at 
60–85%7,8. Genome-wide association studies (GWAS)9–23 have led to valuable insights into 
the genetic etiology of BD. The largest such study has been conducted by the Psychiatric 
Genomics Consortium (PGC), in which genome-wide SNP data from 29,764 BD patients 
and 169,118 controls were analyzed and 30 genome-wide significant loci were identified 
(PGC2)24. SNP-based heritability (ℎSNP2 ) estimation using the same data suggested that 
common genetic variants genome-wide explain ~20% of BD’s phenotypic variance24. 
Polygenic risk scores generated from the results of this study explained ~4% of phenotypic 
variance in independent samples. Across the genome, genetic associations with BD 
converged on specific biological pathways including regulation of insulin secretion25,26, 
retrograde endocannabinoid signaling24, glutamate receptor signaling27 and calcium channel 
activity9.
Despite this considerable progress, only a fraction of the genetic etiology of BD has been 
identified, and the specific biological mechanisms underlying the development of the 
disorder are still unknown. In the present study, we report the results of the third GWAS 
meta-analysis of the PGC Bipolar Disorder Working Group, comprising 41,917 individuals 
with BD and 371,549 controls. These results confirm and expand on many previously 
reported findings, identify novel therapeutic leads, and prioritize genes for functional follow-
up studies28,29. Thus, our results further illuminate the biological etiology of BD.
Results
GWAS results.
We conducted a GWAS meta-analysis of 57 BD cohorts collected in Europe, North America 
and Australia (Supplementary Table 1), totaling 41,917 BD cases and 371,549 controls of 
European descent (effective n = 101,962, see Online Methods). For 52 cohorts, individual-
level genotype and phenotype data were shared with the PGC and cases met international 
consensus criteria (DSM-IV, ICD-9 or ICD-10) for lifetime BD, established using structured 
diagnostic interviews, clinician-administered checklists or medical record review. BD 
GWAS summary statistics were received for five external cohorts (iPSYCH30, deCODE 
genetics31, Estonian Biobank32, Trøndelag Health Study (HUNT)33 and UK Biobank34), in 
which most cases were ascertained using ICD codes. The GWAS meta-analysis identified 64 
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independent loci associated with BD at genome-wide significance (P < 5 × 10−8) (Fig. 1, 
Table 1, and Supplementary Table 2). Using LD Score regression (LDSC)35, the ℎSNP2  of 
BD was estimated to be 18.6% (s.e. = 0.008, P = 5.1 × 10−132) on the liability scale, 
assuming a BD population prevalence of 2%, and 15.6% (s.e. = 0.006, P = 5.0 × 10−132) 
assuming a population prevalence of 1% (Supplementary Table 3). The genomic inflation 
factor (λGC) was 1.38 and the LD Score regression (LDSC) intercept was 1.04 (s.e. = 0.01, 
P = 2.5 × 10−4) (Supplementary Fig. 1). While the intercept has frequently been used as an 
indicator of confounding from population stratification, it can rise above 1 with increased 
sample size and heritability. The attenuation ratio—(LDSC intercept - 1)/(mean of 
association chi-square statistics - 1)—which is not subject to these limitations, was 0.06 (s.e. 
= 0.02), indicating that the majority of inflation of the GWAS test statistics was due to 
polygenicity35,36. Of the 64 genome-wide significant loci, 33 are novel discoveries (i.e. loci 
not overlapping with any locus previously reported as genome-wide significant for BD). 
Novel loci include the major histocompatibility complex (MHC) and loci previously 
reaching genome-wide significance for other psychiatric disorders, including 10 for 
schizophrenia, 4 for major depression, and 3 for childhood-onset psychiatric disorders or 
problematic alcohol use (Table 1).
Enrichment analyses.
Genome-wide analyses using MAGMA37 indicated significant enrichment of BD 
associations in 161 genes (Supplementary Table 4) and 4 gene sets related to synaptic 
signaling (Supplementary Table 5). The BD association signal was enriched amongst genes 
expressed in different brain tissues (Supplementary Table 6), especially genes with high 
specificity of gene expression in neurons (both excitatory and inhibitory) versus other cell 
types, within cortical and subcortical brain regions in mice (Supplementary Fig. 2)38. In 
human brain samples, signal enrichment was also observed in hippocampal pyramidal 
neurons and interneurons of the prefrontal cortex and hippocampus, compared with other 
cell types (Supplementary Fig. 2).
In a gene-set analysis of the targets of individual drugs (from the Drug-Gene Interaction 
Database DGIdb v.239 and the Psychoactive Drug Screening Database Ki DB40), the targets 
of the calcium channel blockers mibefradil and nisoldipine were significantly enriched 
(Supplementary Table 7). Grouping drugs according to their Anatomical Therapeutic 
Chemical (ATC) classes41, there was significant enrichment in the targets of four broad drug 
classes (Supplementary Table 8): psycholeptics (drugs with a calming effect on behavior) 
(especially hypnotics and sedatives, antipsychotics and anxiolytics), calcium channel 
blockers, antiepileptics, and (general) anesthetics (Supplementary Table 8).
eQTL integrative analyses.
We conducted a transcriptome-wide association study (TWAS) using FUSION42 and eQTL 
data from the PsychENCODE Consortium (1,321 brain samples)43. BD-associated alleles 
significantly influenced expression of 77 genes in the brain (Supplementary Table 9 and 
Supplementary Fig. 3). These genes encompassed 40 distinct regions. We performed TWAS 
fine-mapping using FOCUS44 to model the correlation among the TWAS signals and 
prioritize the most likely causal gene(s) in each region. Within the 90%-credible set, FOCUS 
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prioritized 22 genes with a posterior inclusion probability (PIP) > 0.9 (encompassing 20 
distinct regions) and 32 genes with a PIP > 0.7 (29 distinct regions) (Supplementary Table 
10).
We used summary data-based Mendelian randomization (SMR)45,46 to identify putative 
causal relationships between SNPs and BD via gene expression by integrating the BD 
GWAS results with brain eQTL summary statistics from the PsychENCODE43 Consortium 
and blood eQTL summary statistics from the eQTLGen Consortium (31,684 whole blood 
samples)47. The eQTLGen results represent the largest existing eQTL study and provide 
independent eQTL data. Of the 32 genes fine-mapped with PIP > 0.7, 15 were significantly 
associated with BD in the SMR analyses and passed the HEIDI (heterogeneity in dependent 
instruments) test45,46, suggesting that their effect on BD is mediated via gene expression in 
the brain and/or blood (Supplementary Table 11). The genes located in genome-wide 
significant loci are labeled in Figure 1. Other significant genes included HTR6, DCLK3, 
HAPLN4 and PACSIN2.
MHC locus.
Variants within and distal to the major histocompatibility complex (MHC) locus were 
associated with BD at genome-wide significance. The most highly associated SNP was 
rs13195402, 3.2 Mb distal to any HLA gene or the complement component 4 (C4) genes 
(Supplementary Fig. 4). Imputation of C4 alleles using SNP data uncovered no association 
between the five most common structural forms of the C4A/C4B locus (BS, AL, AL-BS, 
AL-BL, and AL-AL) and BD, either before or after conditioning on rs13195402 
(Supplementary Fig. 5). While genetically predicted C4A expression initially showed a 
weak association with BD, this association was non-significant after controlling for 
rs13195402 (Supplementary Fig. 6).
Polygenic risk scoring.
The performance of polygenic risk scores (PRS) based on these GWAS results was assessed 
by excluding cohorts in turn from the meta-analysis to create independent test samples. PRS 
explained ~4.57% of phenotypic variance in BD on the liability scale (at GWAS P-value 
threshold (PT) < 0.1, BD population prevalence 2%), based on the weighted mean R2 across 
cohorts (Fig. 2 and Supplementary Table 12). This corresponds to a weighted mean area 
under the curve (AUC) of 65%. Results per cohort and per wave of recruitment to the PGC 
are in Supplementary Tables 12 and 13 and Supplementary Figure 7. At PT < 0.1, 
individuals in the top 10% of BD PRS had an odds ratio of 3.5 (95% CI 1.7–7.3) of being 
affected with the disorder compared with individuals in the middle decile (based on the 
weighted mean OR across PGC cohorts), and an odds ratio of 9.3 (95% CI 1.7–49.3) 
compared with individuals in the lowest decile. The generalizability of PRS from this meta-
analysis was examined in several non-European cohorts. PRS explained up to 2.3% and 
1.9% of variance in BD in two East Asian samples, and 1.2% and 0.4% in two admixed 
African American samples (Fig. 2 and Supplementary Table 14). The variance explained by 
the PRS increased in every cohort with increasing sample size of the PGC BD European 
discovery sample (Supplementary Fig. 8 and Supplementary Table 14).
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Genetic architecture of BD and other traits.
The genome-wide genetic correlation (rg) of BD with a range of diseases and traits was 
assessed on LD Hub48. After correction for multiple testing, BD showed significant rg with 
16 traits among 255 tested from published GWAS (Supplementary Table 15). Genetic 
correlation was positive with all psychiatric disorders assessed, particularly schizophrenia 
(rg = 0.68) and major depression (rg = 0.44), and to a lesser degree anorexia, attention 
deficit/hyperactivity disorder, and autism spectrum disorder (rg ≈ 0.2). We found evidence of 
positive rg between BD and smoking initiation, cigarettes per day, problematic alcohol use, 
and drinks per week (Fig. 3). BD was also positively genetically correlated with measures of 
sleep quality (daytime sleepiness, insomnia, sleep duration) (Fig. 3). Among 514 traits 
measured in the general population of the UK Biobank, there was significant rg between BD 
and many psychiatric-relevant traits or symptoms, dissatisfaction with interpersonal 
relationships, poorer overall health rating, and feelings of loneliness or isolation 
(Supplementary Table 16).
Bivariate gaussian mixture models were applied to the GWAS summary statistics for BD and 
other complex traits using the MiXeR tool49,50 to estimate the number of variants 
influencing each trait that explain 90% of ℎSNP2  and their overlap between traits. MiXeR 
estimated that approximately 8.6 k (s.e. = 0.2 k) variants influence BD, which is similar to 
the estimate for schizophrenia (9.7 k, s.e. = 0.2 k) and somewhat lower than that for major 
depression (12.3 k, s.e. = 0.6 k) (Supplementary Table 17 and Supplementary Fig. 9). When 
considering the number of shared loci as a proportion of the total polygenicity of each trait, 
the vast majority of loci influencing BD were also estimated to influence major depression 
(97%) and schizophrenia (96%) (Supplementary Table 17 and Supplementary Fig. 9). 
Interestingly, within these shared components, the variants that influenced both BD and 
schizophrenia had high concordance in direction of effect (80%, s.e. = 2%), while the 
portion of concordant variants between BD and MDD was only 69% (s.e. = 1%) 
(Supplementary Table 17).
Genetic and causal relationships between BD and modifiable risk factors.
Ten traits associated with BD from clinical and epidemiological studies were investigated in 
detail for genetic and potentially causal relationships with BD via LDSC35, generalized 
summary statistics-based Mendelian randomization (GSMR)51, and bivariate gaussian 
mixture modeling49. BD has been strongly linked with sleep disturbances52, alcohol use53 
and smoking54, higher educational attainment55,56, and mood instability57. Most of these 
traits had modest but significant genetic correlations with BD (rg = −0.05–0.35) (Fig. 3). 
Examining the effects of these traits on BD via GSMR, smoking initiation was associated 
with BD, corresponding to an OR of 1.49 (95% CI 1.38–1.61) for developing the disorder (P 
= 1.74 × 10−22) (Fig. 3). Testing the effect of BD on the traits, BD was significantly 
associated with reduced likelihood of being a morning person and increased number of 
drinks per week (P < 1.47 × 10−3) (Fig. 3). Positive bi-directional relationships were 
identified between BD and longer sleep duration, problematic alcohol use, educational 
attainment (EA), and mood instability (Fig. 3). Notably, the instrumental variables for mood 
instability were selected from a GWAS conducted in the general population, excluding 
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individuals with psychiatric disorders58. For all of the aforementioned BD-trait 
relationships, the effect size estimates from GSMR were consistent with those calculated 
using the inverse variance weighted regression method, and there was no evidence of bias 
from horizontal pleiotropy. Full MR results are in Supplementary Tables 18 and 19. 
Bivariate gaussian mixture modeling using MiXeR indicated large proportions of variants 
influencing both BD and all other traits tested, particularly educational attainment, where 
approximately 98% of variants influencing BD were estimated to also influence EA. While 
cigarettes per day was a trait of interest, MiXeR could not model these data due to low 
polygenicity and heritability, and the effect of cigarettes per day on BD was inconsistent 
between MR methods, suggesting a violation of MR assumptions (Supplementary Tables 
18–20).
BD subtypes.
We conducted GWAS meta-analyses of bipolar I disorder (BD I) (25,060 cases, 449,978 
controls) and bipolar II disorder (BD II) (6,781 cases, 364,075 controls). The BD I analysis 
identified 44 genome-wide significant loci, 31 of which overlapped with genome-wide 
significant loci from the main BD GWAS (Table 1 and Supplementary Table 21). The 
remaining 13 genome-wide significant loci for BD I all had P < 4.0 × 10−5 in the main BD 
GWAS. One genome-wide significant locus was identified in the GWAS meta-analysis of 
BD II and had a P < 1.1 × 10−4 in the main GWAS of BD (Supplementary Table 21). The 
ℎSNP2  estimates on the liability scale for BD I and BD II were 20.9% (s.e. = 0.009, P = 1.0 × 
10−111) and 11.6% (s.e. = 0.01, P = 3.9 × 10−15), respectively, assuming a 1% population 
prevalence of each subtype. These heritability values are significantly different from each 
other (P = 2.4 × 10−25, block jackknife). The genetic correlation between BD I and BD II 
was 0.85 (s.e. = 0.05, P = 2.88 × 10−54), which is significantly different from 1 (P = 1.6 × 
10−3). The genetic correlation of BD I with schizophrenia (rg = 0.66, s.e. = 0.02) was higher 
than that of BD II (rg = 0.54, s.e. = 0.05), whereas major depression was more strongly 
genetically correlated with BD II (rg = 0.66, s.e. = 0.05) than with BD I (rg = 0.34, s.e. = 
0.03) (Supplementary Table 22).
Discussion
In a GWAS of 41,917 BD cases, we identified 64 associated genomic loci, 33 of which are 
novel discoveries. With a 1.5-fold increase in effective sample size compared with the PGC2 
BD GWAS, this study more than doubled the number of associated loci, representing an 
inflection point in the rate of risk variant discovery. We observed consistent replication of 
known BD loci, including 28/30 loci from the PGC2 GWAS24 and several implicated by 
other BD GWAS15,16,17, including a study of East Asian cases59.
The 33 novel loci discovered here encompass genes of expected biological relevance to BD, 
such as the ion channels CACNB2 and KCNB1. Amongst the 64 BD loci, 17 have 
previously been implicated in GWAS of schizophrenia60, and seven in GWAS of major 
depression61, representing the first overlap of genome-wide significant loci between the 
mood disorders. For these genome-wide significant loci shared across disorders, 17/17 and 
5/7 of the BD index SNPs had the same direction of effect on schizophrenia and major 
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depression, respectively (Supplementary Table 23). More generally, 50/64 and 62/64 BD loci 
had a consistent direction of effect on major depression and schizophrenia, respectively, 
considerably greater than chance (P < 1 × 10−5, binomial test). Bivariate gaussian mixture 
modeling estimated that across the entire genome, almost all variants influencing BD also 
influence schizophrenia and major depression, albeit with variable effects62. SNPs in and 
around the MHC locus reached genome-wide significance for BD for the first time. 
However, unlike in schizophrenia, we found no influence of C4 structural alleles or gene 
expression63. Rather the association was driven by variation outside the classical MHC 
locus, with the index SNP (rs13195402) being a missense variant in BTN2A1, a brain-
expressed gene64 encoding a plasma membrane protein.
The genetic correlation of BD with other psychiatric disorders was consistent with previous 
reports65,66. Our results also corroborate previous genetic and clinical evidence of 
associations between BD and sleep disturbances67, problematic alcohol use68, and 
smoking69. While the genome-wide genetic correlations with these traits were modest (rg = 
−0.05–0.35), MiXeR estimated that, for all traits, more than 55% of trait-influencing 
variants also influence BD (Fig. 3). Taken together, these results point to shared biology as 
one possible explanation for the high prevalence of substance use in BD. However, 
excluding genetic variants associated with both traits, MR analyses suggested that smoking 
is also a putatively “causal” risk factor for BD, while BD has no effect on smoking, 
consistent with a previous report70. (We use the word “causal” with caution here as we 
consider MR an exploratory analysis to identify potentially modifiable risk factors that 
warrant more detailed investigations to understand their complex relationship with BD.) In 
contrast, MR indicated that BD had bi-directional “causal” relationships with problematic 
alcohol use, longer sleep duration, and mood instability. Insights into the relationship of 
such behavioral correlates with BD may have future impact on clinical decision making in 
the prophylaxis or management of the disorder. Higher educational attainment has 
previously been associated with BD in epidemiological studies55,56, while lower educational 
attainment has been associated with schizophrenia and major depression71,72. Here, 
educational attainment had a significant positive effect on risk of BD and vice versa. 
Interestingly, MiXeR estimated that almost all variants that influence BD also influence 
educational attainment. The substantial genetic overlap observed between BD and the other 
phenotypes suggests that many variants likely influence multiple phenotypes, which may be 
differentiated by phenotype-specific effect size distributions among the shared influencing 
variants.
The integration of eQTL data with our GWAS results yielded 15 high-confidence genes for 
which there was converging evidence that their association with BD is mediated via gene 
expression. Amongst these were HTR6, encoding a serotonin receptor targeted by 
antipsychotics and antidepressants73, and MCHR1 (melanin-concentrating hormone receptor 
1), encoding a target of the antipsychotic haloperidol73. We note that, for both of these 
genes, their top eQTLs have opposite directions of effect on gene expression in the brain and 
blood, possibly playing a role in the tissue-specific gene regulation influencing BD74. BD 
was associated with decreased expression of FURIN, a gene with a neurodevelopmental role 
that has already been the subject of functional genomics experiments in neuronal cells 
following its association with schizophrenia in GWAS75. The top association in our GWAS 
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was in the TRANK1 locus on chromosome 3, which has previously been implicated in 
BD12,18,59. Although BD-associated SNPs in this locus are known to regulate TRANK1 
expression76, our eQTL analyses support a stronger but correlated regulation of DCLK3, 
located 87 kb upstream of TRANK143,77. Both FURIN and DCLK3 also encode druggable 
proteins (although they are not targets for any current psychiatric medications)73,78. These 
eQTL results provide promising BD candidate genes for functional follow-up experiments29. 
While several of these are in genome-wide significant loci, many are not the closest gene to 
the index SNP, highlighting the value of probing underlying molecular mechanisms to 
prioritize the most likely causal genes in the loci.
GWAS signals were enriched in the gene targets of existing BD pharmacological agents, 
such as antipsychotics, mood stabilizers, and antiepileptics. However, enrichment was also 
found in the targets of calcium channel blockers used to treat hypertension and GABA-
receptor targeting anesthetics (Supplementary Table 8). Calcium channel antagonists have 
long been investigated for the treatment of BD, without becoming an established therapeutic 
approach, and there is evidence that some antiepileptics have calcium channel-inhibiting 
effects79,80. These results underscore the opportunity for repurposing some classes of drugs, 
particularly calcium channel antagonists, as potential BD treatments81.
BD associations were enriched in gene sets involving neuronal parts and synaptic signaling. 
Neuronal and synaptic pathways have been described in cross-disorder GWAS of multiple 
psychiatric disorders including BD82–84. Dysregulation of such pathways has also been 
suggested by previous functional and animal studies85. Analysis of single-cell gene 
expression data revealed enrichment in genes with high specificity of gene expression in 
neurons (both excitatory and inhibitory) of many brain regions, in particular the cortex and 
hippocampus. These findings are similar to those reported in GWAS data of schizophrenia86 
and major depressive disorder38.
PRS for BD explained on average 4.57% of phenotypic variance (liability scale) across 
European cohorts, although this varied in different waves of the BD GWAS, ranging from 
6.6% in the PGC1 cohorts to 2.9% in the External biobank studies (Supplementary Fig. 7 
and Supplementary Table 12). These results are in line with the ℎSNP2  of BD per wave, 
which ranged from 24.6% (s.e. =0.01) in PGC1 to 11.9% (s.e. = 0.01) in External studies 
(Supplementary Table 3). Some variability in ℎSNP2  estimates may arise from the inclusion 
of cases from population biobanks, who may have more heterogeneous clinical presentations 
or less severe illness than BD patients ascertained via inpatient or outpatient psychiatric 
clinics. Across the waves of clinically ascertained samples within the PGC, ℎSNP2  and the R2 
of PRS also varied, likely reflecting clinical and genetic heterogeneity in the type of BD 
cases ascertained; the PGC1 cohorts consisted mostly of BD I cases9, known to be the most 
heritable of the BD subtypes11,24, while later waves included more individuals with BD II24. 
Overall, the ℎSNP2  of BD calculated from the meta-analysis summary statistics was 18% on 
the liability scale, a decrease of ~2% compared with the PGC2 GWAS24, which may be due 
to the addition of cohorts with lower ℎSNP2  estimates and heterogeneity between cohorts 
(Supplementary Table 3). However, despite differences in ℎSNP2  and R2 of PRS per wave, 
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the genetic correlation of BD between all waves was high (weighted mean rg = 0.94, s.e. = 
0.03), supporting our rationale for combining cases with different BD subtypes or 
ascertainment to increase power for discovery of risk variants. In Europeans, individuals in 
the top 10% of PRS had an OR of 3.5 for BD, compared with individuals with average PRS 
(middle decile), which translates into a modest absolute lifetime risk of the disorder (7% 
based on PRS alone). While PRS are invaluable tools in research settings, the current BD 
PRS lack sufficient power to separate individuals into clinically meaningful risk categories, 
and therefore have no clinical utility at present87,88. PRS from this European BD meta-
analysis yield higher R2 values in diverse ancestry samples than PRS based on any currently 
available BD GWAS within the same ancestry59. However, performance still greatly lags 
behind that in Europeans, with ~2% variance explained in East Asian samples and 
substantially less in admixed African American samples, likely due to differences in allele 
frequencies and LD structures, consistent with previous studies89,90. There is a pressing 
need for more and larger studies in other ancestry groups to ensure that any future clinical 
utility is broadly applicable. Exploiting the differences in LD structure between diverse 
ancestry samples will also assist in the fine-mapping of risk loci for BD.
Our analyses confirmed that BD is a highly polygenic disorder, with an estimated 8.6 k 
variants explaining 90% of its ℎSNP2 . Hence, many more SNPs than those identified here are 
expected to account for the common variant architecture underlying BD. This GWAS marks 
an inflection point in risk variant discovery, and we expect that, from this point forward, the 
addition of more samples will lead to a dramatic increase in genetic findings. Nevertheless, 
fewer genome-wide significant loci have been identified in BD than in a schizophrenia 
GWAS of comparable sample size60. This may be due to the clinical and genetic 
heterogeneity that exists in BD.
Our GWAS of subtypes BD I and BD II identified additional associated loci. Consistent with 
previous findings24, our analysis showed that the two subtypes were highly but imperfectly 
genetically correlated (rg = 0.85), and that BD I is more genetically correlated with 
schizophrenia, while BD II has stronger genetic correlation with major depression. The 
subtypes are sufficiently similar to justify joint analysis as BD, but are not identical in their 
genetic composition, and as such contribute to the genetic heterogeneity of BD91. We 
identified 13 loci passing genome-wide significance for BD I, and one for BD II, which did 
not reach significance in the main BD GWAS, further illustrating the partially differing 
genetic composition of the two subtypes. Understanding the shared and distinct genetic 
components of BD subtypes and symptoms requires detailed phenotyping efforts in large 
cohorts and is an important area for future psychiatric genetics research.
In summary, these new data advance our understanding of the biological etiology of BD and 
prioritize a set of candidate genes for functional follow-up experiments. Several lines of 
evidence converge on the involvement of calcium channel signaling, providing a promising 
avenue for future therapeutic development.
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The meta-analysis sample comprises 57 cohorts collected in Europe, North America and 
Australia, totaling 41,917 BD cases and 371,549 controls of European descent 
(Supplementary Table 1). The total effective n, equivalent to an equal number of cases and 
controls in each cohort (4*ncases*ncontrols/(ncases + ncontrols)), is 101,962. For 52 cohorts, 
individual-level genotype and phenotype data were shared with the PGC. Cohorts have been 
added to the PGC in five waves (PGC19, PGC224, PGC PsychChip, PGC3 and External 
Studies); all cohorts from previous PGC BD GWAS were included. The source and 
inclusion/exclusion criteria for cases and controls for each cohort are described in the 
Supplementary Note. Cases were required to meet international consensus criteria (DSM-IV, 
ICD-9, or ICD-10) for a lifetime diagnosis of BD, established using structured diagnostic 
instruments from assessments by trained interviewers, clinician-administered checklists, or 
medical record review. In most cohorts, controls were screened for the absence of lifetime 
psychiatric disorders and randomly selected from the population. For five cohorts 
(iPSYCH30, deCODE genetics31, Estonian Biobank32, Trøndelag Health Study (HUNT)33 
and UK Biobank34), GWAS summary statistics for BD were shared with the PGC. In these 
cohorts, BD cases were ascertained using ICD codes or self-report during a nurse interview, 
and the majority of controls were screened for the absence of psychiatric disorders via ICD 
codes. Follow-up analyses included four non-European BD case-control cohorts, two from 
East Asia (Japan59 and Korea92), and two admixed African American cohorts22,93, providing 
a total of 5,847 cases and 65,588 controls. These BD cases were ascertained using 
international consensus criteria (DSM-IV)22,93 through psychiatric interviews 
(Supplementary Note).
Genotyping, quality control and imputation.
For 52 cohorts internal to the PGC, genotyping was performed following local protocols and 
genotypes were called using standard genotype calling softwares from commercial sources 
(Affymetrix and Illumina). Subsequently, standardized quality control, imputation and 
statistical analyses were performed centrally using RICOPILI (Rapid Imputation for 
COnsortias PIpeLIne) (version 2018_Nov_23.001)94, separately for each cohort. Briefly, the 
quality control parameters for retaining SNPs and subjects were: SNP missingness < 0.05 
(before sample removal), subject missingness < 0.02, autosomal heterozygosity deviation 
(Fhet < 0.2), SNP missingness < 0.02 (after sample removal), difference in SNP missingness 
between cases and controls < 0.02, SNP Hardy-Weinberg equilibrium (P > 10 × 10−10 in 
psychiatric cases and P > 10 × 10−6 in controls). Relatedness was calculated across cohorts 
using identity by descent and one of each pair of related individuals (pi_hat > 0.2) was 
excluded. Principal components (PCs) were generated using genotyped SNPs in each cohort 
separately using EIGENSTRAT v6.1.495. Based on visual inspection of plots of PCs for 
each dataset (which were all of European descent according to self-report/clinical data), we 
excluded samples to obtain more clearly homogeneous datasets. Genotype imputation was 
performed using the pre-phasing/ imputation stepwise approach implemented in Eagle 
v2.3.596 and Minimac397 to the Haplotype Reference Consortium (HRC) reference panel 
v1.098. Data on the X chromosome were available for 50 cohorts internal to the PGC and 
Mullins et al. Page 11













one external cohort (HUNT), and the X chromosome was imputed to the HRC reference 
panel in males and females separately within each cohort. The five external cohorts were 
processed by the collaborating research teams using comparable procedures and imputed to 
the HRC or a custom reference panel as appropriate. Full details of the genotyping, quality 
control and imputation for each of these cohorts are available in the Supplementary Note. 
Identical individuals between PGC cohorts and the Estonian Biobank and UK Biobank 
cohorts were detected using genotype-based checksums (https://personal.broadinstitute.org/
sripke/share_links/zpXkV8INxUg9bayDpLToG4g58TMtjN_PGC_SCZ_w3.0718d.76) and 
removed from PGC cohorts.
Genome-wide association study.
For PGC cohorts, GWAS were conducted within each cohort using an additive logistic 
regression model in PLINK v1.9099, covarying for PCs 1–5 and any others as required. 
Association analyses of the X chromosome were conducted in males and females separately 
using the same procedures, with males coded as 0 or 2 for 0 or 1 copies of the reference 
allele. Results from males and females were then meta-analyzed within each cohort. For 
external cohorts, GWAS were conducted by the collaborating research teams using 
comparable procedures (Supplementary Note). To control test statistic inflation at SNPs with 
low minor allele frequency (MAF) in small cohorts, SNPs were retained only if cohort MAF 
was > 1% and minor allele count was > 10 in either cases or controls (whichever had smaller 
n). There was no evidence of stratification artifacts or uncontrolled inflation of test statistics 
in the results from any cohort (λGC = 0.97–1.05) (Supplementary Table 1). Meta-analysis of 
GWAS summary statistics was conducted using an inverse variance-weighted fixed effects 
model in METAL (version 2011-03-25)100 across 57 cohorts for the autosomes (41,917 BD 
cases and 371,549 controls) and 51 cohorts for the X chromosome (35,691 BD cases and 
96,731 controls). A genome-wide significant locus was defined as the region around a SNP 
with P < 5 × 10−8, with linkage disequilibrium (LD) r2 > 0.1, within a 3,000 kilobase (kb) 
window. Regional association plots and forest plots of the index SNP for all genome-wide 
significant loci are presented in Supplementary Data 1 and 2, respectively.
Overlap of loci with other psychiatric disorders.
Genome-wide significant loci for BD were assessed for overlap with genome-wide 
significant loci for other psychiatric disorders, using the largest available GWAS results for 
major depression61, schizophrenia60, attention deficit/hyperactivity disorder101, post-
traumatic stress disorder102, lifetime anxiety disorder103, Tourette’s Syndrome104, anorexia 
nervosa105, alcohol use disorder or problematic alcohol use68, autism spectrum disorder106, 
mood disorders91 and the cross-disorder GWAS of the Psychiatric Genomics Consortium66. 
The boundaries of the genome-wide significant loci were calculated in the original 
publications. Overlap of loci was calculated using bedtools v2.29.2107.
Enrichment analyses.
P values quantifying the degree of association of genes and gene sets with BD were 
calculated using MAGMA v1.0837, implemented in FUMA v1.3.6a64,108. Gene-based tests 
were performed for 19,576 genes (Bonferroni-corrected P-value threshold = 2.55 × 10−6). A 
total of 11,858 curated gene sets including at least 10 genes from MSigDB V7.0 were tested 
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for association with BD (Bonferroni-corrected P-value threshold = 4.22 × 10−6). 
Competitive gene-set tests were conducted correcting for gene size, variant density and LD 
within and between genes. Tissue-set enrichment analyses were also performed using 
MAGMA implemented in FUMA, to test for enrichment of association signal in genes 
expressed in 54 tissue types from GTEx V8 (Bonferroni-corrected P-value threshold = 9.26 
× 10−4)64,108.
For single-cell enrichment analyses, publicly available single-cell RNA-seq data were 
compiled from five studies of the adult human and mouse brain86,109–112. The mean 
expression for each gene in each cell type was computed from the single-cell expression data 
(if not provided). For the Zeisel dataset109, we used the mean expression at level 4 (39 cell 
types from 19 regions for the mouse nervous system). For the Saunders dataset110, we 
computed the mean expression of the different classes in each of the 9 different brain regions 
sampled (88 cell types in total). We filtered out any genes with non-unique names, genes not 
expressed in any cell types, non-protein coding genes, and, for mouse datasets, genes that 
had no expert curated 1:1 orthologs between mouse and human (Mouse Genome 
Informatics, The Jackson Laboratory, version 11/22/2016, http://www.informatics.jax.org/
downloads/reports/index.html#homology), resulting in 16,472 genes. Gene expression was 
then scaled to a total of 1 million UMIs (unique molecular identifiers) (or transcript per 
million (TPM)) for each cell type/tissue. Using a previously described method38, a metric of 
gene expression specificity was calculated by dividing the expression of each gene in each 
cell type by the total expression of that gene in all cell types, leading to values ranging from 
0 to 1 for each gene (0 meaning that the gene is not expressed in that cell type and 1 
meaning that all of the expression of the gene is in that cell type). We then selected the top 
10% most specific genes for each cell type/tissue for enrichment analysis. MAGMA v1.0837 
was used to test gene-set enrichment using GWAS summary statistics, covarying for gene 
size, gene density, mean sample size for tested SNPs per gene, the inverse of the minor allele 
counts per gene and the log of these metrics. We excluded any SNPs with INFO score < 0.6, 
with MAF < 1% or with estimated odds ratio > 25 or smaller than 1/25, as well as SNPs 
located in the MHC region (chr6:25–34 Mb). We set a window of 35 kb upstream to 10 kb 
downstream of the gene coordinates to compute gene-level association statistics and used the 
European reference panel from the phase 3 of the 1000 Genomes Project as the reference 
population113. We then used MAGMA to test whether the 10% most specific genes (with an 
expression of at least 1 TPM or 1 UMI per million) for each cell type/tissue were associated 
with BD. The P-value threshold for significance was P < 9.1 × 10−3, representing a 5% false 
discovery rate (FDR) across datasets.
Further gene-set analyses were performed restricted to genes targeted by drugs, assessing 
individual drugs and grouping drugs with similar actions. This approach has been described 
previously41. Gene-level and gene-set analyses were performed in MAGMA v1.0837. Gene 
boundaries were defined using build 37 reference data from the NCBI, available on the 
MAGMA website (https://ctg.cncr.nl/software/magma), extended 35 kb upstream and 10 kb 
downstream to include regulatory regions outside of the transcribed region. Gene-level 
association statistics were defined as the aggregate of the mean and the lowest variant-level 
P value within the gene boundary, converted to a Z-value. Gene sets were defined 
comprising the targets of each drug in the Drug-Gene Interaction database DGIdb v.239 and 
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in the Psychoactive Drug Screening Database Ki DB40, both downloaded in June 201641. 
Analyses were performed using competitive gene-set analyses in MAGMA. Results from the 
drug-set analysis were then grouped according to the Anatomical Therapeutic Chemical 
class of the drug41. Only drug classes with at least 10 valid drug gene sets within them were 
analyzed. Drug-class analysis was performed using enrichment curves. All drug gene sets 
were ranked by their association in the drug set analysis, and then for a given drug class an 
enrichment curve was drawn scoring a “hit” if the drug gene set was within the class, or a 
“miss” if it was outside of the class. The area under the curve was calculated, and a P-value 
for this calculated as the Wilcoxon Mann-Whitney test comparing drug gene sets within the 
class to drug gene sets outside of the class41. Multiple testing was controlled using a 
Bonferroni-corrected significance threshold of P < 5.60 × 10−5 for drug-set analysis and P < 
7.93 × 10−4 for drug-class analysis, accounting for 893 drug-sets and 63 drug classes tested.
eQTL integrative analysis.
A transcriptome-wide association study (TWAS) was conducted using the precomputed gene 
expression weights from PsychENCODE data (1,321 brain samples)43, available online with 
the FUSION software42. For genes with significant cis-SNP heritability (13,435 genes), 
FUSION software (vOct 1, 2019) was used to test whether SNPs influencing gene 
expression are also associated with BD (Bonferroni-corrected P-value threshold < 3.72 × 
10−6). For regions including a TWAS significant gene, TWAS fine-mapping of the region 
was conducted using FOCUS (fine-mapping of causal gene sets, v0.6.10)44. Regions were 
defined using the correlation matrix of predicted effects on gene expression around TWAS 
significant genes44. A posterior inclusion probability (PIP) was assigned to each gene for 
being causal for the observed TWAS association signal. Based on the PIP of each gene and a 
null model, whereby no gene in the region is causal for the TWAS signal, the 90%-credible 
gene set for each region was computed44.
Summary data-based Mendelian randomization (SMR) (v1.03)45,46 was applied to further 
investigate putative causal relationships between SNPs and BD via gene expression. SMR 
was performed using eQTL summary statistics from the eQTLGen (31,684 blood samples)47 
and PsychENCODE43 consortia. SMR analysis is limited to transcripts with at least one 
significant cis-eQTL (P < 5 × 10−8) in each dataset (15,610 in eQTLGen; 10,871 in 
PsychENCODE). The Bonferroni-corrected significance threshold was P < 3.20 × 10−6 and 
P < 4.60 × 10−6 for eQTLGen and PsychENCODE, respectively. The significance threshold 
for the HEIDI test (heterogeneity in dependent instruments) was PHEIDI ≥ 0.0146. While the 
results of TWAS and SMR indicate an association between BD and gene expression, a non-
significant HEIDI test additionally indicates either a direct causal role or a pleiotropic effect 
of the BD-associated SNPs on gene expression.
Complement component 4 (C4) imputation.
To investigate the major histocompatibility complex (MHC; chr6:24–34 Mb on hg19), the 
alleles of complement component 4 genes (C4A and C4B) were imputed in 47 PGC cohorts 
for which individual-level genotype data were accessible, totaling 32,749 BD cases and 
53,370 controls. The imputation reference panel comprised 2,530 reference haplotypes of 
MHC SNPs and C4 alleles, generated using a sample of 1,265 individuals with whole-
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genome sequence data, from the Genomic Psychiatry cohort114. Briefly, imputation of C4 as 
a multi-allelic variant was performed using Beagle v4.1115,116, using SNPs from the MHC 
region that were also in the haplotype reference panel. Within the Beagle pipeline, the 
reference panel was first converted to bref format. We used the conform-gt tool to perform 
strand-flipping and filtering of specific SNPs for which strand remained ambiguous. Beagle 
was run using default parameters with two key exceptions: we used the GRCh37 PLINK 
recombination map, and we set the output to include genotype probability (i.e., GP field in 
VCF) for correct downstream probabilistic estimation of C4A and C4B joint dosages. The 
output consisted of dosage estimates for each of the common C4 structural haplotypes for 
each individual. The five most common structural forms of the C4A/C4B locus (BS, AL, 
AL-BS, AL-BL, and AL-AL) could be inferred with reasonably high accuracy (generally 
0.70 < r2 < 1.00). The imputed C4 alleles were tested for association with BD in a joint 
logistic regression that included (i) terms for dosages of the five most common C4 structural 
haplotypes (AL-BS, AL-BL, AL-AL, BS, and AL), (ii) rs13195402 genotype (top lead SNP 
in the MHC) and (iii) PCs as per the GWAS. The genetically regulated expression of C4A 
was predicted from the imputed C4 alleles using a model previously described63. Predicted 
C4A expression was tested for association with BD in a joint logistic regression that 
included (i) predicted C4A expression, (ii) rs13195402 genotype (top lead SNP in the MHC) 
and (iii) PCs as per the GWAS.
Polygenic risk scoring.
PRS from our GWAS meta-analysis were tested for association with BD in individual 
cohorts, using a discovery GWAS where the target cohort was left out of the meta-analysis. 
Briefly, the GWAS results from each discovery GWAS were pruned for LD using the P-
value informed clumping method in PLINK v1.9099 (r2 0.1 within a 500-kb window) based 
on the LD structure of the HRC reference panel98. Subsets of SNPs were selected from the 
results below nine increasingly liberal P-value thresholds (PT) (5 × 10−8, 1 × 10−4, 1 × 10−3, 
0.01, 0.05, 0.1, 0.2, 0.5, 1). Sets of alleles, weighted by their log odds ratios from the 
discovery GWAS, were summed into PRS for each individual in the target datasets, using 
PLINK v1.90 implemented via RICOPILI94,99. PRS were tested for association with BD in 
the target dataset using logistic regression, covarying for PCs as per the GWAS in each 
cohort. PRS were tested in the external cohorts by the collaborating research teams using 
comparable procedures. The variance explained by the PRS (R2) was converted to the 
liability scale to account for the proportion of cases in each target dataset, using a BD 
population prevalence of 2% and 1%117. The weighted average R2 values were calculated 
using the effective n for each cohort. The odds ratios for BD for individuals in the top decile 
of PRS compared with those in the lowest decile and middle decile were calculated in the 52 
datasets internal to the PGC. To assess cross-ancestry performance, PRS generated from the 
meta-analysis results were tested for association with BD using similar methods in a 
Japanese sample59, a Korean sample92, and two admixed African American samples. Full 
details of the QC, imputation, and analysis of these samples are in the Supplementary Note.
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LD Score regression (LDSC)35 was used to estimate the ℎSNP2  of BD from GWAS summary 
statistics. ℎSNP2  was converted to the liability scale, using a lifetime BD prevalence of 2% 
and 1%. LDSC bivariate genetic correlations attributable to genome-wide SNPs (rg) were 
estimated with 255 human diseases and traits from published GWAS and 514 GWAS of 
phenotypes in the UK Biobank from LD Hub48. Adjusting for the number of traits tested, 
the Bonferroni-corrected P-value thresholds were P < 1.96 × 10−4 and P < 9.73 × 10−5, 
respectively.
MiXeR.
We applied causal mixture models49,118 to the GWAS summary statistics, using MiXeR 
v1.3. MiXeR provides univariate estimates of the proportion of non-null SNPs 
(“polygenicity”) and the variance of effect sizes of non-null SNPs (“discoverability”) in each 
phenotype. For each SNP, i, univariate MiXeR models its additive genetic effect of allele 
substitution, βi, as a point-normal mixture, βi = 1 − π1 N 0, 0 + π1N 0,   σβ2 , where π1 
represents the proportion of non-null SNPs (`polygenicity`) and σβ2 represents variance of 
effect sizes of non-null SNPs (`discoverability`). Then, for each SNP, j, MiXeR incorporates 
LD information and allele frequencies for M = 9,997,231 SNPs extracted from 1000 
Genomes Phase 3 data to estimate the expected probability distribution of the signed test 
statistic, zj = δj + ϵj = N∑i Hirijβi + ϵj, where N is sample size, Hi indicates heterozygosity 
of i-th SNP, rij indicates allelic correlation between i-th and j-th SNPs, and ϵj N 0,   σ02  is 
the residual variance. Further, the three parameters, π1, σβ2, σ02, are fitted by direct 
maximization of the likelihood function. The optimization is based on a set of approximately 
600,000 SNPs, obtained by selecting a random set of 2,000,000 SNPs with minor allele 
frequency of 5% or higher, followed by LD pruning procedure at LD r2 = 0.8 threshold. The 
random SNP selection and full optimization procedure are repeated 20 times to obtain mean 
and standard errors of model parameters. The log-likelihood figures show individual curves 
for each of the 20 runs, each shifted vertically so that best log-likelihood point is shown at 
zero ordinate.
The total number of trait influencing variants is estimated as Mπ1, where M = 9,997,231 
gives the number of SNPs in the reference panel. MiXeR Venn diagrams report the effective 
number of influencing variants, ηMπ_1, where η is a fixed number, η = 0.319, which gives 
the fraction of influencing variants contributing to 90% of trait’s heritability (with rationale 
for this adjustment being that the remaining 68.1% of influencing variants are small and 
cumulatively explain only 10% of trait’s heritability). Phenotypic variance explained on 
average by an influencing genetic variant is calculated as Hσβ2, where H =
1
M ∑iHi = 0.2075
is the average heterozygosity across SNPs in the reference panel. Under the assumptions of 
the MiXeR model, SNP-heritability is then calculated as ℎSNP2 = Mπ1 × Hσβ2.
In the cross-trait analysis, MiXeR models additive genetic effects as a mixture of four 
components, representing null SNPs in both traits (π0); SNPs with a specific effect on the 
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first and on the second trait (π1 and π2, respectively); and SNPs with non-zero effect on 




 where ρ12 indicates correlation of effect sizes within the shared 
component, and σ12 and σ22 correspond to the discoverability parameter estimated in the 
univariate analysis of the two traits. These components are then plotted in Venn diagrams. 
After fitting parameters of the model, the Dice coefficient of polygenic overlap is then 
calculated as 
2π12
π1 + 2π12 + π2
, and genetic correlation is calculated as rg =
ρ12π12
π1 + π12 π2 + π12
. 
Fraction of influencing variants with concordant effect direction is calculated as twice the 
multivariate normal CDF at point (0, 0) for the bivariate normal distribution with zero mean 
and variance-covariance matrix Σ12. All code is available online (https://github.com/
precimed/mixer).
Mendelian randomization.
We selected 17 traits associated with BD in clinical or epidemiological studies for 
Mendelian randomization (MR) to dissect their relationship with BD (Supplementary Note). 
Bi-directional generalized summary statistics-based MR (GSMR)51 analyses were 
performed between BD and the traits of interest using GWAS summary statistics, 
implemented in GCTA software (v1.93.1f beta). The instrumental variables (IVs) were 
selected by a clumping procedure internal to the GSMR software with parameters: --gwas-
thresh 5e-8 --clump-r2 0.01. Traits with less than 10 IVs available were excluded from the 
GSMR analyses to avoid conducting underpowered tests51, resulting in 10 traits tested 
(Bonferroni-corrected P-value threshold < 2.5 × 10−3). The HEIDI-outlier test 
(heterogeneity in dependent instruments) was applied to test for horizontal pleiotropy 
(PHEIDI < 0.01)51. For comparison, the MR analyses were also performed using the inverse 
variance weighted regression method, implemented via the TwoSampleMR R package, using 
the IVs selected by GSMR119,120. To further investigate horizontal pleiotropy, the MR Egger 
intercept test was conducted using the TwoSampleMR package119,120 and MR-PRESSO 
software was used to perform the Global Test and Distortion Test121.
BD subtypes.
GWAS meta-analyses were conducted for BD I (25,060 cases, 449,978 controls from 55 
cohorts, effective n = 64,802) and BD II (6,781 cases, 364,075 controls from 31 cohorts, 
effective n = 22,560) (Supplementary Table 1) using the same procedures described for the 
main GWAS. BD subtypes were defined based on international consensus criteria (DSM-IV, 
ICD-9, or ICD-10), established using structured diagnostic instruments from assessments by 
trained interviewers, clinician-administered checklists or medical record review. In the 
external biobank cohorts, BD subtypes were defined using ICD codes (Supplementary 
Note). LDSC35 was used to estimate the ℎSNP2  of each subtype, and the genetic correlation 
between the subtypes. The difference between the LDSC ℎSNP2  estimates for BD I and BD II 
was tested for deviation from 0 using the block jackknife122. The LDSC genetic correlation 
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(rg) was tested for difference from 1 by calculating a chi-square statistic corresponding to the 
estimated rg as ((rg − 1)/ SE)2.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1 |. Manhattan plot of genome-wide association meta-analysis of 41,917 bipolar disorder 
cases and 371,549 controls.
The x-axis shows genomic position (chromosomes 1–22 and X), and the y-axis shows 
statistical significance as −log10(P value). P values are two-sided and based on an inverse 
variance weighted fixed effects meta-analysis. The red line shows the genome-wide 
significance threshold (P < 5 × 10−8). SNPs in genome-wide significant loci are colored 
green for loci previously associated with bipolar disorder (BD) and yellow for novel 
associations from this study. The genes labeled are those prioritized by integrative eQTL 
analyses or notable genes in novel loci (MHC, CACNB2, KCNB1).
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Figure 2 |. Phenotypic variance in bipolar disorder explained by polygenic risk scores.
Variance explained is presented on the liability scale, assuming a 2% population prevalence 
of bipolar disorder. For European ancestries, the results shown are the weighted mean R2 
values across all 57 cohorts in the PGC3 meta-analysis, weighted by the effective n per 
cohort. The numbers of cases and controls are shown from left to right under the barplot for 
each study. GWAS PT, the color of the bars represents the P value threshold used to select 
SNPs from the discovery GWAS; GAIN-AA, Genetic Association Information Network 
African American cohort; AA-GPC, African American Genomic Psychiatry Cohort.
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Figure 3 |. Relationships between bipolar disorder and modifiable risk factors based on genetic 
correlations, generalized summary statistics-based Mendelian randomization, and bivariate 
gaussian mixture modeling.
Venn diagrams depict MiXeR results of the estimated number of influencing variants shared 
between bipolar disorder (BD) and each trait of interest (grey), unique to BD (blue) and 
unique to the trait of interest (orange). The number of influencing variants and standard error 
are shown in thousands. The size of the circles reflects the polygenicity of each trait, with 
larger circles corresponding to greater polygenicity. The estimated genetic correlation (rg) 
between BD and each trait of interest and standard error from LD Score regression is shown 
below the corresponding Venn diagram, with an accompanying scale (-1 to +1). The arrows 
above and below the Venn diagrams indicate the results of generalized summary statistics-
based Mendelian randomization (GSMR) of BD on the trait of interest, and the trait of 
interest on BD, respectively. The GSMR effect size and standard error is shown inside the 
corresponding arrow. Solid arrows indicate a significant relationship between the exposure 
and the outcome, after correction for multiple comparisons (P < 1.47 × 10−3), and dashed 
arrows indicate a non-significant relationship.
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Table 1 |
Genome-wide significant loci for bipolar disorder from meta-analysis of 41,917 cases and 371,549 controls

















1 1 61105668 rs2126180 1.6E-09 1.058 0.009
A/
G 0.457 LINC01748
2 1 163745389 rs10737496 7.2E-09 1.056 0.009 C/T 0.444 NUF2 CDG










5 2 169481837 rs13417268 2.1E-08 1.064 0.011
C/
G 0.758 CERS6
6 2 193738336 rs2011302 4.3E-08 1.055 0.010
A/
T 0.377 PCGEM1 CDG





8* 3 36856030 rs9834970 6.6E-19 1.087 0.009 C/T 0.481
TRANK1 
(PGC2) SCZ, CDG
9* 3 52626443 rs2336147 3.6E-13 1.070 0.009 T/C 0.498
ITIH1 
(PGC2) SCZ, CDG
10 3 70488788 rs115694474 2.4E-08 1.068 0.012
T/
A 0.799 MDFIC2





12* 4 123076007 rs112481526 1.9E-09 1.065 0.011
G/
A 0.256 KIAA1109 MD





14* 5 78849505 rs6865469 1.7E-08 1.060 0.010
T/
G 0.274 HOMER1





16* 5 137712121 rs10043984 3.7E-08 1.062 0.011 T/C 0.236 KDM3B CDG
17 5 169289206 rs10866641 2.8E-11 1.065 0.009 T/C 0.575 DOCK2






19* 6 98565211 rs1487445 1.5E-15 1.078 0.009 T/C 0.487
POU3F2 
(PGC2) CDG
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24* 7 21492589 rs6954854 5.9E-10 1.060 0.009
G/
A 0.425 SP4












27 7 131870597 rs6946056 3.7E-08 1.055 0.010
C/
A 0.623 PLXNA4










30* 8 10226355 rs3088186 2.1E-08 1.058 0.010 T/C 0.287 MSRA
SCZ, ALC, 
ASD









32* 8 144993377 rs6992333 1.6E-09 1.062 0.010
G/
A 0.410 PLEC
33 9 37090538 rs10973201 2.5E-08 1.101 0.017 C/T 0.110 ZCCHC7
MD, CDG, 
MOOD
34* 9 141066490 rs62581014 2.8E-08 1.067 0.012 T/C 0.366 TUBBP5
35* 10 18751103 rs1998820 4.1E-08 1.087 0.015
T/
A 0.886 CACNB2 SCZ, CDG
36* 10 62322034 rs10994415 1.1E-11 1.125 0.017 C/T 0.082
ANK3 
(PGC2)
37 10 64525135 rs10761661 4.7E-08 1.053 0.009 T/C 0.472 ADO












40 11 64009879 rs4672 3.4E-09 1.107 0.017
A/
G 0.083 FKBP2





42* 11 66324583 rs678397 5.5E-09 1.056 0.009 T/C 0.457
PC (PGC1, 
PGC2)





44 11 79092527 rs12289486 3.3E-08 1.086 0.015 T/C 0.115
ODZ4 
(PGC1)







46 13 113869045 rs35306827 3.6E-09 1.068 0.011
G/
A 0.775 CUL4A
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47 14 99719219 rs2693698 2.0E-08 1.055 0.009
G/
A 0.551 BCL11B SCZ, CDG
48* 15 38973793 rs35958438 3.8E-08 1.066 0.012
G/
A 0.772 C15orf53 CDG





50 15 83531774 rs62011709 1.4E-08 1.064 0.011
T/
A 0.747 HOMER2 SCZ
51* 15 85149575 rs748455 5.0E-11 1.070 0.010 T/C 0.719
ZNF592 
(PGC2) SCZ, CDG
52 15 91426560 rs4702 3.5E-09 1.059 0.010
G/
A 0.446 FURIN SCZ, CDG
53 16 9230816 rs28455634 2.6E-10 1.065 0.010
G/
A 0.620 C16orf72





55 16 89632725 rs12932628 6.7E-09 1.058 0.010
T/
G 0.487 RPL13
56 17 1835482 rs4790841 3.1E-08 1.075 0.013 T/C 0.151 RTN4RL1

























62* 20 48033127 rs237460 4.3E-09 1.057 0.009 T/C 0.412 KCNB1 CDG
63 20 60865815 rs13044225 8.5E-09 1.056 0.010
G/
A 0.440 OSBPL2




CHR, chromosome; BP, GRCh37 base pair position; SNP, single nucleotide polymorphism; OR, odds ratio; s.e., standard error, A1, tested allele; 
A2, other allele; freq, frequency; BD, bipolar disorder; CDG, Cross-disorder GWAS of the Psychiatric Genomics Consortium; MD, major 
depression; SCZ, schizophrenia; MOOD, mood disorders; ASD, autism spectrum disorder; ALC, alcohol use disorder or problematic alcohol use; 
ADHD, attention deficit/hyperactivity disorder.
*
Locus overlaps with genome-wide significant locus for bipolar I disorder.
^
Previous report refers to previous association of a SNP in the locus with the psychiatric disorder at genome-wide significance. PGC1 = PMID 
21926972; PGC2 = PMID 31043756; Hou 2016 = PMID 27329760; Ikeda 2017 = PMID 28115744; Green 2013 = PMID 22565781; Charney 2017 
= PMID 28072414.
+
Novel loci are named using the nearest gene to the index SNP. P values are two-sided and based on an inverse variance weighted fixed effects 
meta-analysis.
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